Teva Pharmaceutical Industries Ltd. ADR

NYS: TEVA

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Teva Pharmaceutical Industries Ltd. ADR

After Hours

--Quotes are delayed by 20 min

Sep 29, 2023, 7:58 p.m.

TEVA

/zigman2/quotes/205657894/composite

10.29

Change

+0.09 +0.88%

Volume

Volume 114,096

Quotes are delayed by 20 min

/zigman2/quotes/205657894/composite

Previous close

$ 10.22

$ 10.20

Change

-0.02 -0.20%

Day low

Day high

$10.16

$10.34

52 week low

52 week high

$7.09

$11.45

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

View Ratios

Fiscal year is January-December. All values ILS millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	65.69B	60.12B	57.29B	51.19B	50.11B
Sales Growth	-	-8.48%	-4.70%	-10.65%	-2.11%
Cost of Goods Sold (COGS) incl. D&A	35.86B	33.32B	30.72B	27.08B	26.72B
COGS excluding D&A	29.24B	27.18B	25.37B	22.78B	22.32B
Depreciation & Amortization Expense	6.62B	6.14B	5.35B	4.3B	4.39B
Depreciation	2.43B	2.17B	1.85B	1.71B	1.94B
Amortization of Intangibles	4.19B	3.97B	3.51B	2.59B	2.46B
COGS Growth	-	-7.10%	-7.79%	-11.86%	-1.33%
Gross Income	29.83B	26.8B	26.57B	24.11B	23.39B
Gross Income Growth	-	-10.14%	-0.86%	-9.26%	-2.98%
Gross Profit Margin	-	-	-	-	46.68%	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	19.51B	17.16B	16.05B	14.2B	14.39B
Research & Development	4.36B	3.6B	3.43B	3.12B	2.82B
Other SG&A	15.15B	13.56B	12.62B	11.08B	11.57B
SGA Growth	-	-12.05%	-6.45%	-11.55%	1.35%
Other Operating Expense	-	-	-	-	-
Unusual Expense	16.96B	11.1B	23.29B	4.35B	16.13B
EBIT after Unusual Expense	(16.96B)	(1.46B)	(12.78B)	5.56B	(7.13B)
Non Operating Income/Expense	553.67M	213.78M	137.56M	(187.35M)	208.32M
Non-Operating Interest Income	140.22M	146.08M	82.54M	-	-
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	3.38B	3.41B	2.6B	3.25B	3.37B
Interest Expense Growth	-	0.90%	-23.85%	25.15%	3.81%
Gross Interest Expense	3.38B	3.41B	2.6B	3.25B	3.37B
Interest Capitalized	-	-	-	-	-
Pretax Income	(9.33B)	(4.51B)	(15.15B)	2.13B	(10.3B)
Pretax Income Growth	-	51.71%	-236.18%	114.03%	-584.53%
Pretax Margin	-	-	-	-	-20.55%	NA
Income Tax	(701.08M)	(990.52M)	(577.76M)	681.56M	(2.14B)
Income Tax - Current Domestic	2.52B	3.15B	625.9M	872.13M	1.44B
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	(3.22B)	(4.14B)	(1.2B)	(190.58M)	(3.59B)
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	(255.26M)	(46.32M)	474.59M	29.07M	70.56M
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(8.89B)	(3.56B)	(14.1B)	1.47B	(8.08B)
Minority Interest Expense	(1.16B)	(3.56M)	(378.29M)	125.97M	(178.08M)
Net Income	(7.73B)	(3.56B)	(13.72B)	1.35B	(7.91B)
Net Income Growth	-	53.95%	-285.50%	109.82%	-686.95%
Net Margin Growth	-	-	-	-	-15.78%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(7.73B)	(3.56B)	(13.72B)	1.35B	(7.91B)
Preferred Dividends	895.22M	-	-	-	-
Net Income Available to Common	(8.63B)	(3.56B)	(13.72B)	1.35B	(7.91B)
EPS (Basic)	(8.45)	(3.26)	(12.53)	1.22	(7.12)
EPS (Basic) Growth	-	61.38%	-284.10%	109.75%	-682.71%
Basic Shares Outstanding	1.02B	1.09B	1.1B	1.1B	1.11B
EPS (Diluted)	(8.45)	(3.26)	(12.53)	1.22	(7.12)
EPS (Diluted) Growth	-	61.38%	-284.10%	109.71%	-685.35%
Diluted Shares Outstanding	1.02B	1.09B	1.1B	1.11B	1.11B
EBITDA	16.94B	15.78B	15.87B	14.21B	13.4B
EBITDA Growth	-	-6.85%	0.60%	-10.49%	-5.70%
EBITDA Margin	-	-	-	-	26.73%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Teva Pharmaceutical Industries Ltd. ADR

Annual Financials for Teva Pharmaceutical Industries Ltd. ADR

Latest News

dow

nasdaq

s&p 500

Kiosk